Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus

Jaylane kadry Ghonima

Status and phase: Unknown; Early Phase 1

Conditions: Oral Lichen Planus

Treatments: Drug: Kenacort A,; Drug: Matrix Metalloproteinase Inhibitors (Orochem)

Study type: Interventional

Funder types: Other

Identifiers

NCT04336488

MMPs in lichen

Details and patient eligibility

About

The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.

Full description

Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the objective disease severity scores will be collected.

Enrollment: 40 estimated patients

Sex: All

Ages: 25+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients diagnosed with erosive OLP confirmed with a biopsy.
• patients should have symptomatic lesions

Exclusion criteria

• Patients who were under anticoagulant medications, suffering from any systemic diseases or having any physical or mental abnormality, pregnant and lactating women, smokers.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

40 participants in 2 patient groups

Orochem (Test)

Experimental group

Description:

fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.

Treatment:

Drug: Matrix Metalloproteinase Inhibitors (Orochem)

Conventional (Control)

Active Comparator group

Description:

fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.

Treatment:

Drug: Kenacort A,